Studies 437 and 438 ADV 10 mgEfficacy Summary

• Statistically significant improvement in

  • Liver histology
  • HBV DNA
  • ALT
  • HBeAg loss and seroconversion (Study 437)

• Histological improvement appears similar across all baseline demographics and disease characteristics

• Continued improvement in efficacy beyond 48 weeks

Previous slide

Next slide

Back to first slide

View graphic version